ライフサイエンスコーパス: glycated hemoglobin

1 holesterol, high C-reactive protein and high glycated hemoglobin).

2 tion to determine levels of CRP, lipids, and glycated hemoglobin.

3 ng glucose and postload glucose but not with glycated hemoglobin.

4 in cholesterol, systolic blood pressure, and glycated hemoglobin.

5 ith adjustment for all covariates as well as glycated hemoglobin.

6 and insulin responses, and the percentage of glycated hemoglobin.

7 thma and a 16% increase in the assessment of glycated hemoglobin.

8 ents than levels of fasting blood glucose or glycated hemoglobin.

9 e foreclosure rate per census-block group on glycated hemoglobin.

10 block group in the prior year and changes in glycated hemoglobin.

11 een the study groups were seen for change in glycated hemoglobin.

12 o five subfractions, four of which contained glycated hemoglobins.

13 points, P<0.001) and had similar control of glycated hemoglobin (0.3 percentage points, P=0.63).

14 (-22.5 vs. -9.9%, p = 0.05), and decrease in glycated hemoglobin (-0.6% vs. -0.3%, p = 0.01).

15 d 10.2 percentage points, respectively), and glycated hemoglobin (10.1 percentage points and 9.4 perc

16 of 1.42 (0.69-2.92) and 2.91 (1.19-7.11) for glycated hemoglobin 5.7-<6.5% and >/=6.5%, respectively,

17 of 1.12 (0.94-1.34) and 1.39 (1.04-1.85) for glycated hemoglobin 5.7-6.4% and >/=6.5%, respectively,

18 omol/L [IQR, 72-89 micromol/L], P = .61) and glycated hemoglobin (5.9% [IQR, 5.6%-6.1%] vs 5.9% [IQR,

19 y; median (IQR), 10 (5-9) y of T2D duration; glycated hemoglobin 7.0% +/- 0.8%; body mass index (in k

20 urther adjustment for C-reactive protein and glycated hemoglobin A(1c) did not materially attenuate t

21 (excluding gestational diabetes mellitus) or glycated hemoglobin A(1c) of 6.5% or greater.

22 fasting plasma lipid, lipoprotein, glucose, glycated hemoglobin A(1c), and fructosamine concentratio

23 llected at each visit for the assay of serum glycated hemoglobin A1c (A1c), hsCRP, d-8-iso, MMP-2, an

24 g plasma glucose >/=200 mg/dl (11.1 mmol/l), glycated hemoglobin A1c (HbA1c) >6.5%, self-reported phy

25 nfidence intervals (CIs) were calculated for glycated hemoglobin A1c (HbA1c), fasting plasma glucose

26 se [FCG] level, 2-hour CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, an

27 agnosis, sex, race/ethnicity, net worth, and glycated hemoglobin A1c fraction (HbA1c).

28 While adjusting for duration of diabetes, glycated hemoglobin A1c level, and other factors, we fou

29 Glycated hemoglobin A1c levels improved to 7.0% [6.4%-7.

30 The mean (SD) glycated hemoglobin A1c of the 50 patients (26 men and 2

31 ciation of baseline waist circumference with glycated hemoglobin A1c reduction is likely due to selec

32 The only significant predictor of glycated hemoglobin A1c reduction was waist circumferenc

33 are well-adhered to, whereas guidelines for glycated hemoglobin A1c testing for type 2 diabetes mell

34 Tested as continuous variables, glycated hemoglobin A1C, but neither body mass index nor

35 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin we

36 We collected data on histories of patients' glycated hemoglobin A1c, hypertension, hyperlipidemia, s

37 tions, pain (numeric rating scale), level of glycated hemoglobin A1c, level of C-reactive protein, bo

38 Complete remission was defined as glycated hemoglobin (A1C) less than 6% and fasting blood

39 sted difference, 1.0 percentage points), and glycated hemoglobin (adjusted difference, 3.4 percentage

40 ysis (OCT) over a 4-y period, independent of glycated hemoglobin, age, and sex.

41 syndrome (69.2 vs. 51.9%), fast glycemia and glycated hemoglobin, albuminuria, triglycerides and uric

42 This review examines glycated hemoglobin, an indicator of long-term average b

43 y is to investigate the relationship between glycated hemoglobin and circulating levels of interleuki

44 In contrast, glycated hemoglobin and death from any cause were found

45 We compared the prognostic value of glycated hemoglobin and fasting glucose for identifying

46 rvention also produced greater reductions in glycated hemoglobin and greater initial improvements in

47 erum concentrations of metabolic parameters (glycated hemoglobin and low-density lipoprotein), inflam

48 abetes Association diagnostic cut points for glycated hemoglobin and microvascular outcomes (chronic

49 group also had significantly lower levels of glycated hemoglobin and required less insulin.

50 Glycated hemoglobin and retinal vascular histopathology

51 ic red blood cells correlates with levels of glycated hemoglobin and that the mechanical properties o

52 cholesterol, triglycerides, blood pressure, glycated hemoglobin, and fasting glucose and report the

53 ar reductions in insulin, insulin C-peptide, glycated hemoglobin, and homeostasis model assessment of

54 measured in urine, with diabetes prevalence, glycated hemoglobin, and insulin resistance in American

55 ats maintained in poor glycemic control (PC, glycated hemoglobin approximately 11%) or in good glycem

56 mately 11%) or in good glycemic control (GC, glycated hemoglobin approximately 6%) for 6 months, or i

57 rs are modestly effective in reducing HbA1c (glycated hemoglobin) ( approximately 0.5%) and while the

58 ta add to the evidence supporting the use of glycated hemoglobin as a diagnostic test for diabetes.

59 of Germany or Austria), body mass index, and glycated hemoglobin as covariates were used to account f

60 iculated thrombocytosis that correlates with glycated hemoglobin as well as increased plasma S100A8/A

61 e variation, complicates the clinical use of glycated hemoglobin assays for the diagnosis and managem

62 Mean glycated hemoglobin at baseline was similar in both grou

63 ears after baseline on the basis of either a glycated hemoglobin concentration of at least 6.5% or us

64 Glycated hemoglobin concentration predicts cardiovascula

65 moking, alcohol consumption, fasting status, glycated hemoglobin concentration, physical activity, an

66 hod for measuring the hemoglobin A1c (HbA1c, glycated hemoglobin) concentration, hemoglobin (Hb) conc

67 Glycated hemoglobin concentrations predict cardiovascula

68 lin-based regimen to oral therapy had better glycated hemoglobin control than patients who added a bi

69 moglobin glycation index (HGI), a measure of glycated hemoglobin controlled for blood glucose variati

70 se of new 2010 American Diabetes Association glycated hemoglobin cut points for the diagnosis of diab

71 s improved, for example, fasting glucose and glycated hemoglobin decreased from 6.1 to 5.4 mmol/mol a

72 Glycated hemoglobin decreased significantly from 8.2 +/-

73 ass index, duration of diabetes, 7-year mean glycated hemoglobin, diabetes treatment, duration of ins

74 liflozin group than in the placebo group for glycated hemoglobin (difference, -0.46 percentage points

75 ssociated with fasting glucose, 2-h glucose, glycated hemoglobin, fasting insulin, or thigh intramusc

76 e intervention group had significantly lower glycated hemoglobin, fasting plasma glucose, plaque inde

77 The primary endpoint was change in glycated hemoglobin from baseline.

78 poor glycemic control (PC, approximately 12% glycated hemoglobin [GHb]) for 3 months followed by in g

79 Glycated hemoglobin (Hb A(1c)) and plasma lipids were as

80 body mass index (BMI; in kg/m(2)) of 32, and glycated hemoglobin (Hb A(1c)) of 5.9%.

81 ion of plasma carotenoids with blood lipids, glycated hemoglobin (Hb A(1c)), and C-reactive protein (

82 t composition was associated with subsequent glycated hemoglobin (Hb A1c) concentrations during inten

83 Improved glycated hemoglobin (Hb A1c) delays the progression of m

84 oad glucose (PG), 2-h postload insulin (PI), glycated hemoglobin (Hb A1c), and homeostasis model asse

85 Glycated hemoglobin, Hb A1c, was used as a reliable age

86 the association of macronutrient intake and glycated hemoglobin (HbA(1c)) in adults with diabetes.

87 Glycated hemoglobin (HbA(1c)) values are higher in Afric

88 Levels of glucose and glycated hemoglobin (HbA(1c)) were significantly reduced

89 omes, including height, weight, and level of glycated hemoglobin (HbA(1c)).

90 sed by fasting and 2-h post-OGTT glucose and glycated hemoglobin (HbA(1c)).

91 is low, which may improve concentrations of glycated hemoglobin (HbA(1c), a marker of dysglycemia).

92 s: colorectal screening rates; diabetes with glycated hemoglobin (HbA1c level) less than 9.0%; diabet

93 om among 321 people with type 2 diabetes and glycated hemoglobin (HbA1c) >58 mmol/mol.

94 ype 2 diabetes were recruited: subjects with glycated hemoglobin (HbA1c) </=7% and subjects with HbA1

95 ; betaPFOA=1.71 pM; 95% CI: 0.72, 2.71), and glycated hemoglobin (HbA1c) (betaPFOS=0.03%; 95% CI: 0.0

96 ) concentration (-37.0 mg/dL; P < 0.001) and glycated hemoglobin (HbA1c) [-0.97% (-10.6 mmol/mol); P

97 nt increases in hippocampal FC, decreases in glycated hemoglobin (HbA1c) and body fat, and increases

98 We examined the association between baseline glycated hemoglobin (HbA1c) and high-sensitivity cardiac

99 A 66-year-old man affected by DME, with glycated hemoglobin (HbA1c) at 6.9%, refractory to laser

100 d the association between food label use and glycated hemoglobin (HbA1c) concentrations.

101 After 12 months, glycated hemoglobin (HbA1c) decreased from 10.3+/-2.4% t

102 In recent years, glycated hemoglobin (HbA1c) has been increasingly accept

103 has been developed for the determination of glycated hemoglobin (HbA1c) in human blood samples.

104 The level of Glycated hemoglobin (HbA1c) is accordingly examined for

105 Glycated hemoglobin (HbA1c) is one of the most important

106 Glycated hemoglobin (HbA1c) is used to diagnose type 2 d

107 lycemia from birth, resulting in an elevated glycated hemoglobin (HbA1c) level that mimics recommende

108 ex, waist circumference, fat percentage, and glycated hemoglobin (HbA1c) level were recorded chairsid

109 n leakage area at month 36 (P = 0.0137), and glycated hemoglobin (HbA1c) levels at month 36 (P = 0.00

110 ed the association between periodontitis and glycated hemoglobin (HbA1c) levels in individuals withou

111 (20-50 U) and metformin (>/=1500 mg/d) with glycated hemoglobin (HbA1c) levels of 7% to 10% and a bo

112 nfluence of periodontal status on changes of glycated hemoglobin (HbA1c) levels of patients with type

113 Glycated hemoglobin (HbA1c) levels ranged from 4.7-12.6%

114 Glycated hemoglobin (HbA1c) levels were measured at base

115 Glycated hemoglobin (HbA1c) levels were measured from an

116 Glycated hemoglobin (HbA1c) levels were measured, and pr

117 Glycated proteins, such as glycated hemoglobin (HbA1c) or glycated albumin (GA) in

118 hievement of good glycemic control, of which glycated hemoglobin (HbA1c) remains the standard clinica

119 type 2 diabetes of 6 years' duration, has a glycated hemoglobin (HbA1C) value of 7.4% despite taking

120 in or loss and glycemic control (assessed by glycated hemoglobin (HbA1c) values) in patients from the

121 In multivariable analyses, glycated hemoglobin (HbA1c) was inversely associated wit

122 Higher levels of glycated hemoglobin (HbA1c) were associated with all-cau

123 stasis: fasting glucose, fasting insulin and glycated hemoglobin (HbA1c) were studied and compared be

124 glucose, C-reactive protein, triglycerides, glycated hemoglobin (HbA1c), and total, low-density lipo

125 The relationship between delayed GE and glycated hemoglobin (HbA1c), complications of DM, and ga

126 eplacement of other sugars and its effect on glycated hemoglobin (HbA1c), fasting blood glucose, insu

127 agnostic accuracies of random blood glucose, glycated hemoglobin (HBA1c), fructosamine, and Homeostas

128 glycemia (diabetes status, fasting glucose, glycated hemoglobin (HbA1c), fructosamine, glycated albu

129 ent of glycated blood proteins, particularly glycated hemoglobin (HbA1c), is an important diagnostic

130 Blood glycated hemoglobin (HbA1c), reflecting the average bloo

131 ed with the diabetes GRS on fasting insulin, glycated hemoglobin (HbA1c), the homeostasis model asses

132 Measurement of glycated hemoglobin (HbA1c), the most widely accepted in

133 led trials (RCTs) that assessed the outcomes glycated hemoglobin (HbA1c), weight, body mass index (BM

134 dy mass index, random blood sugar (RBS), and glycated hemoglobin (HbA1c).

135 trol was assessed according to percentage of glycated hemoglobin (HbA1c).

136 sensor was developed for the recognition of glycated hemoglobin (HbA1c).

137 body mass index (in kg/m(2)): 34.6 +/- 4.3; glycated hemoglobin (HbA1c): 7.3 +/- 1.1%; duration of d

138 n [n = 136; mean +/- SD age: 12.8 +/- 2.6 y; glycated hemoglobin (HbA1c): 8.1% +/- 1.0%; 69.1% using

139 .7%) was associated with a reduction in mean glycated hemoglobin (HbA1c, -1.3 +/- 1.8%, P < 0.001), f

140 d by measurement of the cutoff ratio between glycated hemoglobins (HbA1c) and total hemoglobin (Hb),

141 ol/L, 2-hr plasma glucose >/=11.1 mmol/L, or glycated hemoglobin [HbA1c] >/=6.5%) was detected in 46%

142 8 of whom had poor glycemic control (average glycated hemoglobin [HbA1c] >/=8% during the year) while

143 tensive glycemic control in type 2 diabetes (glycated hemoglobin [HbA1c] level <7%) is an established

144 cose [RBG], fasting blood glucose [FBG], and glycated hemoglobin [HbA1c]) and survival in all lung tr

145 In 2006, 56% of incident cases had a glycated hemoglobin (hemoglobin A1c) test as one of the

146 justment for metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholestero

147 There was no change in glycated hemoglobin in either group: mean, 7.4 (95% CI,

148 h both incidence of T2D and increased plasma glycated hemoglobin in individuals without T2D, providin

149 ities are associated with elevated levels of glycated hemoglobin in nondemented community-dwelling el

150 and with low HDL concentrations and elevated glycated hemoglobin in obese and diabetic patients.CCK r

151 in elevated plasma glucose concentration and glycated hemoglobin in the diabetic state.

152 We measured glycated hemoglobin in whole-blood samples from 11,092 b

153 es were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell

154 Levels of blood glucose/glycated hemoglobin (International Federation of Clinica

155 A 1% increase in absolute concentrations of glycated hemoglobin is associated with about 10-20% incr

156 closures do not affect health in general, 2) glycated hemoglobin is insensitive to local foreclosure

157 For every 1% higher glycated hemoglobin, left ventricular mass was higher by

158 dard therapy or aggressive therapy (targets: glycated hemoglobin level <6.0%, low-density lipoprotein

159 val [CI], 0.8 to 15.0) for glycemic control (glycated hemoglobin level <7.0%), 9.4 percentage points

160 ed optimal diabetes care (n = 448) (targets: glycated hemoglobin level <7.0%, low-density lipoprotein

161 omly assigned 708 patients with a suboptimal glycated hemoglobin level (7.0 to 10.0%) who were receiv

162 At 1 year, the baseline mean glycated hemoglobin level (8.3% in the two study groups)

163 At 2 years, the average baseline glycated hemoglobin level (8.65+/-1.45%) had decreased i

164 wer; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0

165 , 1.02; 95% CI, 1.01-1.04) and knowing one's glycated hemoglobin level (odds ratio, 2.00; 95% CI, 1.3

166 on of T2DM (P = 0.006), a higher presurgical glycated hemoglobin level (P = 0.019), insulin treatment

167 nd with periventricular hyperintensities for glycated hemoglobin level (r = 0.28) and normalized PEFR

168 white matter hyperintensities were found for glycated hemoglobin level (r = 0.31), hypertension (r =

169 , sulfonylurea) with stable body weight, and glycated hemoglobin level 7.0% to 10.0%.

170 tiple linear regression analysis showed that glycated hemoglobin level and hypertension were predicti

171 outcomes included safety and changes in the glycated hemoglobin level and insulin dose.

172 eters) for 84.2% of participants and data on glycated hemoglobin level for 71.3% of participants.

173 os for death from any cause according to the glycated hemoglobin level for patients with diabetes as

174 Glycated hemoglobin level had poorer test characteristic

175 The primary end point was a glycated hemoglobin level lower than 7.0% at week 24, wi

176 n, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% with no severe

177 mg per deciliter [5.6 mmol per liter] and a glycated hemoglobin level of <6.5% in the absence of pha

178 with 4.3% over 3 years among patients with a glycated hemoglobin level of 10%.

179 was 1.0% over 5 years among patients with a glycated hemoglobin level of 6%, as compared with 4.3% o

180 point was the proportion of patients with a glycated hemoglobin level of 6.0% or less 12 months afte

181 The primary outcome was a glycated hemoglobin level of 6.0% or less with or withou

182 The primary end point was a glycated hemoglobin level of 6.0% or less.

183 to metformin and sulfonylurea resulted in a glycated hemoglobin level of 6.5% or less in a minority

184 he respective proportions of patients with a glycated hemoglobin level of 6.5% or less were 17.0%, 23

185 in levels, the proportion of patients with a glycated hemoglobin level of 6.5% or less, the rate of h

186 bin level, the proportion of patients with a glycated hemoglobin level of 6.5% or less, the rate of h

187 MI of 35 or more, a BMI of 40 or more, and a glycated hemoglobin level of 6.5% or more were lower in

188 diagnosis of obstructive sleep apnea, with a glycated hemoglobin level of 6.5-8.5%, and an oxygen des

189 ients younger than 55 years of age who had a glycated hemoglobin level of 6.9% or less (</=52 mmol pe

190 ng those younger than 55 years of age with a glycated hemoglobin level of 6.9% or less, as compared w

191 trols were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (</=52 mmol p

192 l study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of

193 story of at least 5 years of diabetes, and a glycated hemoglobin level of 7.0% or more were randomly

194 ol improved in all three groups, with a mean glycated hemoglobin level of 7.5+/-1.8% in the medical-t

195 level of 130 mg per deciliter or more, and a glycated hemoglobin level of 8 percent or more.

196 e was loss of glycemic control, defined as a glycated hemoglobin level of at least 8% for 6 months or

197 , but intensive glucose control, targeting a glycated hemoglobin level of less than 6.5%, did not.

198 t a dose of 1000 mg twice daily) to attain a glycated hemoglobin level of less than 8% and were rando

199 e patient's current state of retinopathy and glycated hemoglobin level reduced the frequency of eye e

200 r mean percentage reduction from baseline in glycated hemoglobin level than did patients who received

201 The mean (SD) glycated hemoglobin level was 7.4% (0.5%).

202 At 24 months, the mean glycated hemoglobin level was 7.5+/-1.2% in each group,

203 iabetes was 16.4 years, and the mean (+/-SD) glycated hemoglobin level was 8.4+/-1.7%; 83.9% of the p

204 s was 49+/-8 years, 66% were women, the mean glycated hemoglobin level was 9.2+/-1.5%, and the mean B

205 The average glycated hemoglobin level was 9.2+/-1.5%.

206 /-8 years, 68% were women, the mean baseline glycated hemoglobin level was 9.3+/-1.5%, and the mean b

207 pproximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%.

208 etes had poor glycemic control (mean [+/-SD] glycated hemoglobin level, 9.0+/-2.4%), and the rates of

209 y lipoprotein, and low-density lipoprotein), glycated hemoglobin level, and mean fasting blood glucos

210 te reduction of 1.5 percentage points in the glycated hemoglobin level, as compared with the standard

211 Secondary outcomes included the glycated hemoglobin level, mean daily insulin dose, rate

212 ith placebo did not affect the insulin dose, glycated hemoglobin level, or hypoglycemia rate.

213 Outcome measures at 1 year were the mean glycated hemoglobin level, the proportion of patients wi

214 points included the change from baseline in glycated hemoglobin level, weight, systolic blood pressu

215 1.13; P = .003) for each unit of increase in glycated hemoglobin level.

216 counting for glycemic control in the form of glycated hemoglobin level.

217 primary safety outcome was the change in the glycated hemoglobin level.

218 y end point was the change from the baseline glycated hemoglobin level.

219 e injection-therapy group reached the target glycated hemoglobin level.

220 C-peptide levels, insulin requirements, and glycated hemoglobin level.

221 lycemia, and, in adults, resulted in a lower glycated hemoglobin level.

222 [-1.4 to -0.5] [30.9%]) and less increase in glycated hemoglobin levels (0.11% [0.02% to 0.20%] vs 0.

223 greater overall 12-month improvement across glycated hemoglobin levels (difference, 0.58%), LDL chol

224 f 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean differenc

225 The phenomenon of a discrepancy between glycated hemoglobin levels and other indicators of avera

226 Elevated glycated hemoglobin levels below the thresholds accepted

227 The difference in glycated hemoglobin levels between the intensive-therapy

228 ween-group differences in blood pressure and glycated hemoglobin levels during the trial were no long

229 re or hospitalization for asthma, control of glycated hemoglobin levels for diabetes, and control of

230 of glucose levels and 10,208 measurements of glycated hemoglobin levels from 2067 participants withou

231 previously been found to reduce glucose and glycated hemoglobin levels in humans.

232 clines in cortisol levels, blood glucose and glycated hemoglobin levels increased soon after treatmen

233 Glycated hemoglobin levels measured by all three primary

234 we observed no significant effect on average glycated hemoglobin levels or on the percentage of parti

235 e fully attenuated after adjustment for mean glycated hemoglobin levels over the entire follow-up.

236 sults show that interindividual variation in glycated hemoglobin levels was evident in diabetes patie

237 Median glycated hemoglobin levels were 8.4% in the standard-the

238 Between-group differences in glycated hemoglobin levels were lost after the first yea

239 Glycated hemoglobin levels were lower with pump therapy

240 Glycated hemoglobin levels were measured using three pri

241 e first year of the study or subsequently if glycated hemoglobin levels were more than 6.5%.

242 Glycated hemoglobin levels were significantly lower with

243 Median glycated hemoglobin levels were similar for patients rec

244 At 1 year, mean glycated hemoglobin levels were similar in the biphasic

245 we evaluated 708 patients who had suboptimal glycated hemoglobin levels while taking metformin and su

246 the greatest degree of improvement (average glycated hemoglobin levels, 7.69+/-0.57% in the medical-

247 ), sequential multiple analyzer 24 (SMA 24), glycated hemoglobin levels, and screening for anti-white

248 erapy resulted in significant improvement in glycated hemoglobin levels, as compared with injection t

249 Secondary outcomes included glycated hemoglobin levels, insulin dose, and body mass

250 tic state, as assessed by plasma glucose and glycated hemoglobin levels, maintained significant hyper

251 Outcome measures were glycated hemoglobin levels, the proportion of patients w

252 Interindividual and ethnic variation in glycated hemoglobin levels, unrelated to blood glucose v

253 men, C-reactive protein, lipoprotein(a), and glycated hemoglobin levels.

254 on self-report or fasting serum glucose and glycated hemoglobin levels.

255 progression was also closely related to mean glycated hemoglobin levels.

256 al history, antidiabetic medication use, and glycated hemoglobin levels.

257 c blood pressures, and high triglyceride and glycated hemoglobin levels.

258 ere among metabolic surgery patients (higher glycated hemoglobin levels; greater percentage of insuli

259 es included blood-pressure, cholesterol, and glycated hemoglobin levels; screening for depression; me

260 utcome was based on simultaneous modeling of glycated hemoglobin, low-density lipoprotein (LDL) chole

261 ith type 2 diabetes in good glucose control (glycated hemoglobin < 7.5%) before and after 7 d of a VL

262 For type 2 diabetes (glycated hemoglobin <6.5% without medication), sample-si

263 Glycated hemoglobin measurements were compared in patien

264 amer-based microfluidic system for automatic glycated hemoglobin measurements.

265 ptical coherence tomography, blood pressure, glycated hemoglobin, medications, and changes in such pa

266 /m(2)) of 39.2 (95% CI: 35.2, 43.3) and mean glycated hemoglobin of 5.3% (95% CI: 4.9%, 5.6%), were s

267 nduced diabetic rats had no effect on raised glycated hemoglobin or sciatic nerve polyol levels, conf

268 gnificantly associated with fasting glucose, glycated hemoglobin, or visceral abdominal fat.

269 Assessing the types and amounts of glycated hemoglobins present in erythrocytes could provi

270 the intention-to-treat population, the mean glycated hemoglobin profile improved in the intervention

271 asma fasting glucose (r = -0.1, P = 0.0006), glycated hemoglobin (r = -0.08, P = 0.006), and homeosta

272 ceride/HDL-C ratio (r = 0.16, p = 0.03), and glycated hemoglobin (r = 0.16, p = 0.03) with pioglitazo

273 ger correlation was observed between PAV and glycated hemoglobin (r = 0.22, p = 0.0003) than fasting

274 luble leptin receptor (reduction of 43%) and glycated hemoglobin (reduction of 28%).

275 o a greater improvement in glycemic control [glycated hemoglobin reductions of -0.12% (P = 0.04), -0.

276 positive correlation of chemerin with IL-6, glycated hemoglobin, sampled-site clinical attachment le

277 The proportion of patients who reached the glycated hemoglobin target (<7%) was greater in the pump

278 x, diabetes, waist/hip ratios, and levels of glycated hemoglobin, the NAFLD activity score was associ

279 We used admission glycated hemoglobin to estimate premorbid baseline blood

280 rotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive prote

281 meters controlling for sex, body mass index, glycated hemoglobin, use of oral hypoglycemic drugs, and

282 The glycated hemoglobin value at baseline was associated wit

283 mg per deciliter (2.6 mmol per liter), and a glycated hemoglobin value of 9.0% or lower, according to

284 ological factors assessed, insulin index and glycated hemoglobin values explained 15% and 16% of the

285 periodontitis presented higher glycemia and glycated hemoglobin values in contrast to patients with

286 For glycated hemoglobin values of less than 5.0%, 5.0 to les

287 The changes in glycated hemoglobin values were similar in the two group

288 d nocturnal hypoglycemia, without increasing glycated hemoglobin values.

289 mination showed significant improvement when glycated hemoglobin was added to models including fastin

290 Recently, glycated hemoglobin was also recommended for this purpos

291 In the absence of diagnosed diabetes, glycated hemoglobin was cross sectionally associated wit

292 n or albuminuria or blood pressure, although glycated hemoglobin was lowered with both diets.

293 Glycated hemoglobin was recently recommended for use as

294 nity-based population of nondiabetic adults, glycated hemoglobin was similarly associated with a risk

295 diabetes at baseline, clinical categories of glycated hemoglobin were associated with risk of chronic

296 adhesion molecule 1, C-peptide, insulin, and glycated hemoglobin were evident, but they were not sign

297 rular basement membrane and higher levels of glycated hemoglobin were independent predictors of progr

298 lar blood glucose levels regardless of which glycated hemoglobins were measured.

299 ignificant thresholds in the associations of glycated hemoglobin with kidney disease risk or retinopa

300 e of risk thresholds in the relationships of glycated hemoglobin with these outcomes.